Nanomedicines are highly promising for cancer therapy due to their minimal side effects.
However, little is known regarding their host immune response, which may limit their clinical …

The combinational chemo-immunotherapy as a novel treatment strategy has been widely
studied and applied in clinic to enhance antitumor therapeutic efficacy and relieve side …

The effective chemotherapeutic drug, doxorubicin (DOX), elicits immunogenic cell death
(ICD) and additional anticancer immune responses during chemotherapy. However, it also …

Liver metastasis is the major cause of colorectal cancer (CRC)-related death, and 1/4 CRC
patients present liver metastases at first diagnosis. Despite significant improvements in …

Local delivery of immune-activating agents has shown promise in overcoming an
immunosuppressive tumor microenvironment (TME) and stimulating antitumor immune …

The limited lymphocyte infiltration and exhaustion of tumoricidal functions in solid tumors
remain a formidable obstacle to cancer immunotherapy. Herein, we designed a macrophage …

Prostate cancer is one of the leading causes of cancer death in adult men and is a
multistage disease with therapeutic challenges of local recurrent advanced tumors and …

Cancer recurrence and metastasis are still common causes of postsurgery death in patients
with solid tumors, suggesting that additional consolidation therapeutic strategies are …

Nanoparticles have great advantages in overcoming the delivery barriers for
chemotherapeutics, but the effect on overall tumor immune landscape after drug delivery is …

Although the strategies to induce dendritic cells (DCs) maturation and promote their antigen
presentation can stimulate the tumor immune response, the endogenous deficiency and …